Alnylam issues 2nd annual patient access philosophy report highlighting broad access to the company's approved therapies

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today published two new reports: the second annual update on its patient access philosophy and its first-ever rare disease trend report. together, the reports illuminate both the strategies by which the company has been able to maximize access for its approved medicines around the world, and the barriers associated with coverage for rare disease therapies. the patient access p
ALNY Ratings Summary
ALNY Quant Ranking